Brian J Yoder

Summary

Publications

  1. ncbi request reprint The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study
    Sarah M Short
    Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
    Breast J 13:130-9. 2007
  2. pmc The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
    David G Hicks
    Clarient Inc, Aliso Veijo, California, USA
    BMC Cancer 10:108. 2010
  3. ncbi request reprint Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast
    Brian J Yoder
    Department of Pathology, University of Florida, Gainesville, Florida 33805, USA
    Breast J 13:172-9. 2007
  4. doi request reprint Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk
    Brian J Yoder
    Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Am J Surg Pathol 32:765-72. 2008
  5. pmc Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
  6. ncbi request reprint Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR
    David G Hicks
    Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Surg Pathol 30:1097-104. 2006
  7. ncbi request reprint Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Brian Z Ring
    Applied Genomics Inc, 863 Mitten Rd 103, Burlingame, CA, USA
    J Clin Oncol 24:3039-47. 2006
  8. ncbi request reprint The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
    Erinn Downs-Kelly
    Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Surg Pathol 29:1221-7. 2005
  9. ncbi request reprint The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study
    David G Hicks
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 36:348-56. 2005
  10. ncbi request reprint The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course
    Brian J Yoder
    Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 11:186-92. 2005

Collaborators

  • Irina Rufforny
  • David G Hicks
  • Joseph P Crowe
  • R R Tubbs
  • Robert J Weil
  • Danny R Welch
  • Erinn Downs-Kelly
  • Sarah M Short
  • Shannon M Tarr
  • Brian Z Ring
  • James D Pettay
  • Nichole L Prescott
  • Thomas G Budd
  • Simas Laniauskas
  • Kara A Coleman
  • Toni K Choueiri
  • Rod Beck
  • Douglas T Ross
  • Robert S Seitz
  • William J Shasteen
  • Maggie C U Cheang
  • G Thomas Budd
  • Torsten O Nielsen
  • Noel C Estopinal
  • Marek Skacel
  • Patrick Roche
  • Thomas Grogan
  • Mark Stoler

Detail Information

Publications10

  1. ncbi request reprint The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study
    Sarah M Short
    Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
    Breast J 13:130-9. 2007
    ..Further study of a role for paxillin expression in predicting response to cytotoxic regimens or targeted treatments is warranted...
  2. pmc The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
    David G Hicks
    Clarient Inc, Aliso Veijo, California, USA
    BMC Cancer 10:108. 2010
    ..Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients...
  3. ncbi request reprint Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast
    Brian J Yoder
    Department of Pathology, University of Florida, Gainesville, Florida 33805, USA
    Breast J 13:172-9. 2007
    ..The goal of this review is to present what is currently known about the molecular profiles of infiltrating ductal and lobular carcinoma and how they relate to conventional histopathology and biologic behavior...
  4. doi request reprint Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk
    Brian J Yoder
    Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Am J Surg Pathol 32:765-72. 2008
    ..The 3 most important features of stage IA tumors in predicting tumor recurrence were the depth of invasion, presence of SCC at the surgical margins, and the histologic grade...
  5. pmc Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
    ....
  6. ncbi request reprint Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR
    David G Hicks
    Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Surg Pathol 30:1097-104. 2006
    ....
  7. ncbi request reprint Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Brian Z Ring
    Applied Genomics Inc, 863 Mitten Rd 103, Burlingame, CA, USA
    J Clin Oncol 24:3039-47. 2006
    ..We have used gene expression data to guide the production of hundreds of novel antibody reagents to discover novel diagnostic tools for stratifying carcinoma patients...
  8. ncbi request reprint The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
    Erinn Downs-Kelly
    Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Surg Pathol 29:1221-7. 2005
    ..These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma...
  9. ncbi request reprint The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study
    David G Hicks
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 36:348-56. 2005
    ..If TOP2A gene dosage can be confirmed to correlate with tumor responsiveness to anthracycline-based therapy in the clinical setting, FISH testing for TOP2A status may be warranted to aid in the selection of the most appropriate therapy...
  10. ncbi request reprint The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course
    Brian J Yoder
    Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 11:186-92. 2005
    ..If so, then fascin may represent a new molecular target for therapeutic intervention in patients with ER-negative breast cancer...